Physician profile
Deepak Chandra
NPI 1790030286
$2,756.24
in general payments reported to CMS, 2019-2025
27 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.07 · 2020: $14.56 · 2021: $345 · 2022: $273 · 2023: $644 · 2024: $1,033 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001 · Education: $87.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.93 |
| Education | $87.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.00 | 2021-2025 | Ofev, Stiolto Respimat, Jascayd |
| Genzyme Corporation | $271.14 | 2024-2025 | |
| Glaxosmithkline, LLC. | $268.49 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $161.71 | 2021-2025 | Airsupra, Fasenra |
| Mylan Specialty L.P. | $161.54 | 2022-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $152.57 | 2024-2025 | Dupixent |
| Alk-Abello, INC | $149.76 | 2024 | Odactra, Grastek |
| Merck Sharp & Dohme LLC | $147.23 | 2021-2025 | Zerbaxa, Delstrigo, Pifeltro |
| Abiomed | $140.95 | 2021 | |
| Baxter Healthcare | $122.95 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Grifols USA, LLC | $105.71 | 2022-2024 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $78.99 | 2024 | |
| United Therapeutics Corporation | $78.93 | 2023-2025 | Tyvaso, Orenitram |
| Abbvie INC. | $73.36 | 2022-2023 | Teflaro |
| Advanced Respiratory, INC | $69.66 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $57.14 | 2024-2025 | Dexcom G6 Transmitter |
| Philips North America LLC | $55.34 | 2019-2023 | |
| Verona Pharma, INC. | $50.94 | 2025 | Ohtuvayre |
| Insmed, INC. | $48.23 | 2024-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $31.50 | 2023 | Opsumit, Uptravi |
| Viiv Healthcare Company | $29.63 | 2024 | Apretude |
| Gilead Sciences, INC. | $23.60 | 2024 | Biktarvy |
| Pulmonx Corporation | $22.89 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Qiagen, LLC | $20.40 | 2024 | |
| Novo Nordisk INC | $19.04 | 2024 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $16.98 | 2021 | |
| Allergan, INC. | $14.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.